Complications of chemotherapy in neuro-oncology

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 873-885

  Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855549331     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00029-X     Document Type: Chapter

References (104)

1. Aubard Y., Piver P., Teissier M.P. Indications for cryopreservation of ovarian tissue. Presse Med 2000, 29:960-964.
2. Baggiolini M., Bickel M.H., Messiha F.S. Demethylation in vivo of Natulan, a tumour-inhibiting methylhydrazine derivative. Experientia 1965, 21:334-336.
3. Baruchel S., Diezi M., Hargrave D., et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 2006, 42:2335-2342.
4. Brandes A.A., Tosoni A., Amista P., et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004, 63:1281-1284.
5. Brandes A.A., Tosoni A., Basso U., et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004, 22:4779-4786.
6. Brandes A.A., Tosoni A., Vastola F., et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A phase II study. Cancer 2004, 101:2079-2085.
7. Brandes A.A., Nicolardi L., Tosoni A., et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-oncol 2006, 8:253-260.
8. Brandes A.A., Tosoni A., Cavallo G., et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2006, 95:1155-1160.
9. Braun M.S., Quirke P., Seymour M.T. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Rev Anticancer Ther 2007, 7:489-501.
10. Byrne J., Fears T.R., Gail M.H., et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992, 166:788-793.
11. Chamberlain M.C., Wei-Tsao D.D., Blumenthal D.T., et al. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. Cancer 2008, 112:2038-2045.
12. Chiarelli A.M., Marrett L.D., Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. Am J Epidemiol 1999, 150:245-254.
13. Ciesielski M.J., Fenstermaker R.A. Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation. J Neurooncol 1999, 41:223-234.
14. Cohen R.J., Wiernik P.H., Walker M.D. Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases. Cancer Treat Rep 1976, 60:1257-1261.
15. de Chaisemartin L., Loriot M.A. Pharmacogenetics of anticancer drugs. Pathol Biol (Paris) 2005, 53:116-124.
16. de Jonge M.J., Loos W.J., Gelderblom H., et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 2000, 18:2104-2115.
17. De Vita S., De Matteis S., Laurenti L., et al. Secondary Ph+ acute lymphoblastic leukemia after temozolomide. Ann Hematol 2005, 84:760-762.
18. Doolittle N.D., Peereboom D.M., Christoforidis G.A., et al. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting. J Neurooncol 2007, 81:81-91.
19. Eramo A., Ricci-Vitiani L., Zeuner A., et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006, 13:1238-1241.
20. Esteller M., Garcia-Foncillas J., Andion E., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
21. Fauroux B., Meyer-Milsztain A., Boccon-Gibod L., et al. Cytotoxic drug-induced pulmonary disease in infants and children. Pediatr Pulmonol 1994, 18:347-355.
22. Fazeny-Dorner B., Veitl M., Wenzel C., et al. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs 2003, 14:437-442.
23. Fazeny-Dorner B., Veitl M., Wenzel C., et al. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Br J Cancer 2003, 88:496-501.
24. Follezou J.Y., Fauchon F., Chiras J. Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma 1989, 36:349-352.
25. Frenay M., Giroux B., Khoury S., et al. Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer 1991, 27:852-856.
26. Frenay M., Lebrun C., Lonjon M., et al. Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 2000, 36:1026-1031.
27. Frenay M.P., Fontaine D., Vandenbos F., et al. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol 2005, 12:685-690.
28. Gamelin E., Boisdron-Celle M., Morel A., et al. Pharmacogenetics of anti-cancer drugs. Ann Pharm Fr 2007, 65:390-401.
29. Ganiere V., Christen G., Bally F., et al. Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. Nat Clin Pract Oncol 2006, 3:339-343.
30. Genot J.Y., Krulik M., Poisson M., et al. Two cases of acute leukemia following treatment of malignant glioma. Cancer 1983, 52:222-226.
31. Gilbert M., O'Neill A., Grossman S., et al. A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol 2000, 47:145-152.
32. Gill S., Shapiro J., Westerman D., et al. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma. J Clin Oncol 2007, 25:4493-4494.
33. Glas M., Koch H., Hirschmann B., et al. Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series. Oncology 2007, 72:302-307.
34. Grossman S.A., O'Neill A., Grunnet M., et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003, 21:1485-1491.
35. Halnan K.E. Fifty years of the National Health Service 1948-1998: a personal history of progress in the treatment of cancer. Clin Oncol (R Coll Radiol) 1999, 11:55-60.
36. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
37. Herrlinger U., Rieger J., Koch D., et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006, 24:4412-4417.
38. Holoye P.Y., Jenkins D.E., Greenberg S.D. Pulmonary toxicity in long-term administration of BCNU. Cancer Treat Rep 1976, 60:1691-1694.
39. Houghton P.J., Stewart C.F., Cheshire P.J., et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000, 6:4110-4118.
40. Izaki S., Goto H., Okuda K., et al. Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. Int J Hematol 2007, 86:253-260.
41. Kamiyama H., Takano S., Tsuboi K., et al. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 2005, 131:205-213.
42. Kempin S., Sundaresan N., Shapiro W.B., et al. Acute nonlymphocytic leukemia following treatment of malignant glioma. Report of two cases. J Neurosurg 1984, 60:1287-1290.
43. Kesari S., Schiff D., Doherty L., et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncol 2007, 9:354-363.
44. Kiu M.C., Chang C.N., Cheng W.C., et al. Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J Neurooncol 1995, 25:215-220.
45. Kocak Z., Hatipoglu C.A., Ertem G., et al. Trimethoprim-sulfamethoxazole induced rash and fatal hematologic disorders. J Infect 2006, 52:e49-e52.
46. Kodym R. Secondary malignancies after multimodality treatment regimens. Front Radiat Ther Oncol 2002, 37:84-91.
47. Kong D.S., Lee J.I., Kim W.S., et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 2006, 16:1117-1121.
48. Levin V.A., Uhm J.H., Jaeckle K.A., et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 2000, 6:3878-3884.
49. Lieberman A., Ruoff M., Estey E., et al. Irreversible pulmonary toxicity after single course of BCNU. Am J Med Sci 1980, 279:53-56.
50. Lord J., Coleman E.A. Chemotherapy for glioblastoma multiforme. J Neurosci Nurs 1991, 23:68-70.
51. Macdonald D.R., Kiebert G., Prados M., et al. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest 2005, 23:138-144.
52. Madajewicz S., Chowhan N., Iliya A., et al. Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 1991, 67:2844-2849.
53. Mahaley M.S., Hipp S.W., Dropcho E.J., et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989, 70:371-378.
54. Markman M., Blessing J.A., Alvarez R.D., et al. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2000, 77:112-115.
55. Martinez R., Schackert G., Yaya-Tur R., et al. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 2007, 83:91-93.
56. Massing U., Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist Updat 2000, 3:171-177.
57. Matsuo T., Sugita T., Shimose S., et al. Postradiation malignant fibrous histiocytoma and osteosarcoma of a patient with high telomerase activities. Anticancer Res 2005, 25:2951-2955.
58. Medical Research Council Brain Tumor Working Party Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001, 19:509-518.
59. Mertens A.C., Yasui Y., Liu Y., et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 2002, 95:2431-2441.
60. Nakatsu S., Kondo S., Kondo Y., et al. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 1997, 39:417-423.
61. Neugut A.I., Robinson E., Nieves J., et al. Poor survival of treatment-related acute nonlymphocytic leukemia. JAMA 1990, 264:1006-1008.
62. Neuwelt E.A. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004, 54:131-140.
63. Newton H.B., Newton C.L. Attempted dose intensified cyclophosphamide, etoposide, and granulocyte colony-stimulating factor for treatment of malignant astrocytoma. J Neurooncol 1995, 24:285-292.
64. Newton H.B., Page M.A., Junck L., et al. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurooncol 1989, 7:39-45.
65. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 2007, 110:1542-1550.
66. Noronha V., Berliner N., Ballen K.K., et al. Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncol 2006, 8:280-283.
67. O'Driscoll B.R., Kalra S., Gattamaneni H.R., et al. Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995, 107:1355-1357.
68. Pedersen-Bjergaard J., Ersboll J., Sorensen H.M., et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985, 103:195-200.
69. Perry J.R., Brown M.T., Gockerman J.P. Acute leukemia following treatment of malignant glioma. J Neurooncol 1998, 40:39-46.
70. Perry J.R., Bélanger K., Mason W.P., et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma RESCUE study. J Clin Oncol 2010, 28:2051-2057.
71. Piribauer M., Fazeny-Dorner B., Rossler K., et al. Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. Anticancer Drugs 2003, 14:137-143.
72. Prados M.D., Scott C., Curran W.J., et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999, 17:3389-3395.
73. Preussmann R. Carcinogenicity of nitrosoureas in humans. IARC Sci Publ 1986, 78:223-229.
74. Quencer R.M., Neuwelt E.A. Advances in the understanding of the blood-brain barrier in neuro-oncology. AJNR Am J Neuroradiol 2002, 23:1807-1810.
75. Rahman A.M., Yusuf S.W., Ewer M.S. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine 2007, 2:567-583.
76. Reardon D.A., Quinn J.A., Rich J.N., et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005, 104:1478-1486.
77. Robustelli della Cuna G., Paoletti P., Bernardo G., et al. Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors. Neurosurgery 1982, 11:408-411.
78. Rosner F. Cancer and secondary leukemia. Bull Cancer 1983, 70:55-60.
79. Rutishauser A., Bollag W. Studies on the action mechanism of procarbazine (Natulan). Experientia 1967, 23:222-223.
80. Sanderson B.J., Shield A.J. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996, 355:41-57.
81. Sathornsumetee S., Cao Y., Marcello J.E., et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008, 26:271-278.
82. Schmidt F., Fischer J., Herrlinger U., et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006, 66:587-589.
83. Schuller E., Seidl R., Wandl C., et al. Prolonged second response to cisplatin, etoposide, and ifosfamide in a child with a recurrent brainstem glioblastoma. Pediatr Hematol Oncol 2001, 18:253-258.
84. Shen Y.C., Chiu C.F., Chow K.C., et al. Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant 2004, 34:609-614.
85. Stewart D.J., Richard M.T., Benoit B., et al. Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J Neurooncol 1984, 2:29-34.
86. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
87. Stupp R., Hegi M.E., Gilbert M.R., et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007, 25:4127-4136.
88. Tang P., Roldan G., Brasher P.M., et al. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 2006, 78:311-316.
89. Taphoorn M.J., van den Bent M.J., Mauer M.E., et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol 2007, 25:5723-5730.
90. Terasaki M., Bouffet E., Katsuki H., et al. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol 2008, 69:46-50.
91. Tfayli A., Hentschel P., Madajewicz S., et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J Neurooncol 1999, 42:73-77.
92. Tucker M.A., Meadows A.T., Boice J.D., et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987, 78:459-464.
93. von der Weid N.X. Adult life after surviving lymphoma in childhood. Support Care Cancer 2008, 16:339-345.
94. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
95. Wagner S., Peters O., Fels C., et al. Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J Neurooncol 2008, 86:175-181.
96. Weller M., Muller B., Koch R., et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003, 21:3276-3284.
97. Wick A., Felsberg J., Steinbach J.P., et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007, 25:3357-3361.
98. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27-46.
99. Wolff J.E., Molenkamp G., Westphal S., et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer 2000, 89:2131-2137.
100. Wolff J.E., Berrak S., Koontz Webb S.E., et al. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neurooncol 2008, 88:57-63.
101. Wu H.M., Lee A.G., Lehane D.E., et al. Ocular and orbital complications of intraarterial cisplatin. A case report. J Neuroophthalmol 1997, 17:195-198.
102. Yasui W., Tahara E. Pediatric tumors and secondary cancer. The Ninth International Symposium of the Hiroshima Cancer Seminar, September 1999, Hiroshima, Japan. J Cancer Res Clin Oncol 2000, 126:357-359.
103. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
104. Zustovich F., Cartei G., Ceravolo R., et al. A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. Anticancer Res 2007, 27:1019-1024.